Core Viewpoint - The article emphasizes the lessons learned from Japan's healthcare system during its "lost decades," particularly the consequences of poor decision-making in medical education and resource allocation, which may serve as a cautionary tale for China's healthcare system as it faces similar challenges of aging population and healthcare reform [6][21]. Group 1: Historical Context of Japan's Healthcare System - In the 1970s, Japan's government implemented a "one medical school per prefecture" policy, leading to a doubling of doctors and a "golden age" for healthcare, with free medical services for the elderly starting in 1973 [8][9]. - By the 1980s, the government miscalculated the future need for doctors, predicting a surplus and reducing medical school admissions by 10% by 1995, ignoring the aging population's increasing healthcare demands [9][10]. Group 2: Consequences of Policy Decisions - The 1990s marked a period of "medical collapse" in Japan, characterized by a financial crisis that led to drastic cuts in healthcare spending, resulting in increased workloads for doctors and a deterioration of their social standing [12][14]. - By 1995, 40% of doctors worked over 80 hours a week due to a shortage of medical staff, while public sentiment turned against doctors, blaming them for high healthcare costs [13][14]. Group 3: Training and Working Conditions of Medical Professionals - The plight of resident doctors in Japan during the 1990s was dire, as they were treated as unpaid laborers without legal protections, leading to tragic incidents like the death of a young resident due to overwork [16][17]. - The "Morita incident" sparked outrage and prompted a societal reflection on the treatment of young doctors, highlighting the need for respect and proper working conditions in medical training [17][18]. Group 4: Reforms and Recovery - After reaching a crisis point in 2003, Japan initiated the "New Clinical Training System" in 2004, recognizing resident doctors as workers entitled to salaries and labor protections, which allowed for a more equitable training environment [19][20]. - The reform also broke the monopoly of university hospitals on residency placements, enabling medical students to choose their training hospitals, thus improving the overall quality of medical education [20]. Group 5: Implications for China's Healthcare System - China's aging population is projected to exceed 400 million elderly individuals by 2035, raising concerns about the adequacy of healthcare resources and the potential for a similar crisis as seen in Japan [22]. - The article warns against misjudging the implications of demographic changes and emphasizes the need for structural adjustments in medical education rather than a reduction in training capacity [22][23]. - It stresses the importance of respecting the dignity of medical professionals and ensuring that the training system does not treat students as expendable resources, which could lead to a talent shortage in the future [23][24].

Core Viewpoint - The article discusses the ethical challenges within the medical profession, emphasizing that the commercialization of healthcare can lead to moral corruption among medical practitioners [14][29]. Group 1: Ethical Standards in Medicine - There is a societal expectation for doctors to maintain high ethical standards, as highlighted by historical references to medical ethics [3][4]. - The article argues that the medical profession is not immune to human flaws, and doctors can succumb to unethical practices, especially in a profit-driven environment [5][12]. Group 2: Case Study of Medical Malpractice - The case of Liu Xiangfeng, who engaged in severe malpractice, including unnecessary surgeries and organ trafficking, illustrates the potential for extreme unethical behavior in the medical field [11][12]. - The complicity of colleagues and the systemic issues within healthcare institutions contribute to the perpetuation of such unethical practices [10][12]. Group 3: Impact of Medical Commercialization - The commercialization of healthcare prioritizes financial gain over patient care, leading to a culture where unethical behavior can thrive [14][16]. - The article critiques the healthcare system's focus on profit, suggesting that it creates an environment conducive to corruption and malpractice [29][30]. Group 4: Need for Reform - The current healthcare system requires significant reform to address the ethical issues and ensure transparency in medical practices [27][30]. - The article advocates for a shift away from profit-driven metrics to a model that prioritizes patient welfare and ethical standards [28][30].

Group 1 - Trump's announcement to sign an executive order mandating a 30%-80% reduction in prescription drug prices has caused significant market volatility, particularly impacting Chinese biotech firm BeiGene, which saw a 10% drop in stock price on May 12 [1] - The biopharmaceutical sector experienced a rebound on May 13, with companies like Junshi Biosciences and BeiGene recovering some losses, indicating a complex market reaction to the announcement [1] - The announcement reflects deeper issues within the U.S. healthcare reform landscape, highlighting the political challenges and the lack of a clear implementation path for such policies [2] Group 2 - The U.S. pharmaceutical pricing system is characterized by a high investment cycle, with the top ten global pharmaceutical companies, eight of which are American, investing a total of $120.5 billion in R&D in 2023 [3] - The lobbying efforts of the Pharmaceutical Research and Manufacturers of America (PhRMA) are significant, with political contributions reaching $382.6 million in 2023, a 67% increase from 2016, indicating the industry's strong influence on policy [3] - The American Medical Association (AMA) controls pricing for medical services, which affects insurance premiums and creates a closed-loop profit chain among patients, insurers, and pharmaceutical companies [4] Group 3 - The U.S. healthcare reform challenges stem from the interplay of market beliefs, decentralized governance, and populist political demands, complicating any unilateral executive actions [5] - Legal challenges may arise from the Takings Clause of the U.S. Constitution, which protects corporate property rights, potentially hindering the implementation of price controls [5] - Cultural resistance to government intervention in healthcare is prevalent, with 63% of Americans believing that such actions would lower the quality of care, complicating the acceptance of unilateral pricing policies [5] Group 4 - The market reaction to Trump's pricing announcement reflects a pessimistic outlook on the uncertainty surrounding pharmaceutical companies, particularly in the context of global pricing dynamics [6] - The disparity in drug pricing between the U.S. and China highlights the critical role of the U.S. pricing system as a valuation anchor for global biopharmaceutical innovation [6] - Successful healthcare reforms in other countries, such as Germany and Japan, demonstrate that market access and affordability can coexist, suggesting that a balanced approach is necessary for U.S. healthcare reform [6] Group 5 - Chinese pharmaceutical companies are increasingly focusing on global expansion, leveraging technological advancements and compliance strategies to navigate market challenges [7] - Companies like BeiGene and Junshi Biosciences are establishing production bases in the U.S. to mitigate tariff risks and integrate into the global supply chain [7] - The recent policy turbulence underscores that Chinese innovative drug companies are evolving from followers to leaders in setting industry standards, as evidenced by significant licensing deals and advancements in cutting-edge therapies [7]